Class / Patent application number | Description | Number of patent applications / Date published |
514647000 | Amino nitrogen and a ring bonded directly to the same ring and any other amino nitrogen in the compound is bonded directly to one of the rings | 30 |
20080227864 | Lhr1 Activators as Medicaments - Methods or prevention or treatment of diseases or conditions caused by low plasma apoA-1 levels, the use of LRH1 activators in such methods and methods for identification of compounds useful in such treatment. | 09-18-2008 |
20080293822 | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use - The invention provides novel arylbicyclo[3.1.0]hexylamines, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety. | 11-27-2008 |
20090076160 | Use of R (+) -N-propargyl-1-aminoindan to treat or prevent hearing loss - A method of treating or inhibiting hearing loss in a mammalian subject, comprising administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof effective to treat or inhibit the hearing loss in the subject. | 03-19-2009 |
20100010095 | Process for purifying rasagiline base - Disclosed is crystalline R(+)-N-propargyl-1-aminoindan and racemic N-propargyl-1-aminoindan characterized by colorless crystals a pharmaceutical composition comprising the same, and the process for the manufacture and the validation thereof. Also disclosed is pure liquid R(+)-N-propargyl-1-aminoindan and a pharmaceutical composition comprising the same, and the process for the manufacture thereof. | 01-14-2010 |
20100292340 | Treatment of CNS Disorders With trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine - Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful. | 11-18-2010 |
20100305212 | THERAPEUTIC COMPOUNDS - The invention relates to protein binding interacting/binding compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating 5-HT2C disorders, including diseases and disorders mediated by GPCRs. | 12-02-2010 |
20100324147 | ARYLCYCLOPROPYLAMINES AND METHODS OF USE - Described herein are arylcyclopropylamine compounds that may inhibit enzymes comprising an amine oxidase domain, such as LSD1, MAO A and/or MAO B. | 12-23-2010 |
20110251287 | HCI POLYMORPHS OF 3-((2-(DIMETHYLAMINO)METHYL (CYCLOHEX-1-YL))PHENOL - A crystalline salt of 3-[2-(dimethylamino)methyl(cyclohex-1-yl)]phenol and hydrogen chloride, preferably in a 1:1 composition, including various crystalline forms of this salt, processes for preparing the various crystalline forms of this salt, pharmaceutical compositions containing the various crystalline forms of this salt, and the use of this salt as a pharmacologically active agent in a pharmaceutical composition to treat or inhibit pain or other disorders or disease states. | 10-13-2011 |
20110306674 | Pharmaceutical Combination - A pharmaceutical combination comprising as components (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and (b) at least one NMDA-antagonist, a pharmaceutical formulation and a dosage form comprising such a combination, and a method of treating pain, e.g. inflammatory pain or neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, with component (a) being administered either before or after component (b), and with components (a) or (b) being administered to the mammal either via the same pathway of administration or via different pathways of administration. | 12-15-2011 |
20120004315 | Selective Estrogen Receptor Modulator - The present invention provides a compound represented by the following formula (I); | 01-05-2012 |
20120142784 | LYSINE-SPECIFIC DEMETHYLASE 1(LSD1) IS A BIOMARKER FOR BREAST CANCER - The present invention relates to novel biomarker for breast cancer, namely LSD1 and its application in inter alia the diagnosis of breast cancer. Furthermore, the present invention discloses a method of determining the LSD1 protein amount and the effect of LSD1 inhibitors on cancer cells selected from breast cancer, lung carcinoma and sarcoma. | 06-07-2012 |
20130116332 | FORMULATIONS, SALTS AND POLYMORPHS OF TRANSNORSERTRALINE AND USES THEREOF - Provided herein are pharmaceutical compositions comprising transnorsertraline, salts and polymorphic forms of transnorsertraline, methods of making the compositions, and methods for their use for the treatment of CNS diseases, including depression. | 05-09-2013 |
20130190407 | CALCIUM RECEPTOR-ACTIVE MOLECULES - The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca | 07-25-2013 |
20130197095 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES - The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions. | 08-01-2013 |
20130289126 | CELL AGING AS A UNIQUE BIOMARKER OF MAJOR DEPRESSION - The present invention provides methods of determining whether a subject is a suitable candidate for an anti-depressant treatment to alleviate a mood disorder by measuring telomere length and telomerase activity. The present invention also provides methods of assessing the efficacy of an anti-depressant treatment to alleviate a mood disorder and of predicting whether a subject is at risk of developing depression. | 10-31-2013 |
20140057988 | ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE - A method for treating, ameliorating or preventing the onset of anxiety in a subject comprises administering to such subject an NMDA receptor antagonist in an amount that is sub-anesthetic and hypo-analgetic. The NMDA receptor antagonist may comprise ketamine and its pharmaceutically acceptable salts, and is administered as a premedication. Instances of use in this manner include administration prior to an anxiety causing event, such as a medical or a dental procedure. The administration of the NMDA receptor antagonist composition is particularly useful as a premedication for adults. | 02-27-2014 |
20140080915 | Abuse-proofed dosage forms - The invention relates to a form of administration which is secured against misuse and which is thermoformed without extrusion, comprising at least one synthetic or natural polymer having a resistance to breaking of at least 500 N in addition to one or several active ingredients with a misuse potential and, optionally physiologically compatible auxiliary substances. The invention also relates to a method for the production thereof. | 03-20-2014 |
20140155490 | THERAPEUTIC COMPOUNDS - The invention relates to protein binding interacting/binding compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating 5-HT2C disorders, including diseases and disorders mediated by GPCRs. | 06-05-2014 |
20140256821 | INTRANNASAL ADMINISTRATION OF KETAMINE TO TREAT DEPRESSION - Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years). | 09-11-2014 |
20140275278 | PHARMACEUTICAL COMPOSITION OF S-KETAMINE HYDROCHLORIDE - The present invention is directed to an aqueous formulation of S-ketamine hydrochloride, preferably for nasal administration, wherein the formulation does not contain an antimicrobial preservative. | 09-18-2014 |
20140309311 | Pharmaceutical Combination - A pharmaceutical combination comprising as components (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and (b) at least one NMDA-antagonist, a pharmaceutical formulation and a dosage form comprising such a combination, and a method of treating pain, e.g. inflammatory pain or neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, with component (a) being administered either before or after component (b), and with components (a) or (b) being administered to the mammal either via the same pathway of administration or via different pathways of administration. | 10-16-2014 |
20150057360 | METHODS FOR THE TREATMENT OF TINNITUS INDUCED BY COCHLEAR EXCITOTOXICITY - The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method. | 02-26-2015 |
20150315127 | THERAPEUTIC COMPOUNDS - The invention relates to protein binding interacting/binding compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating 5-HT2C and/or RSK disorders, including diseases and disorders mediated by GPCRs and/or RSKs. | 11-05-2015 |
20150315128 | BICYCLIC COMPOUNDS - Disclosed are compounds of Formula (I) | 11-05-2015 |
20160045455 | METHOD FOR THE TREATMENT OF DEPRESSION - The present invention is directed to method for the treatment of depression, for example, treatment resistant depression; wherein the treatment regimen is adjusted depending on the patient's genotype at SNP rs4306882. | 02-18-2016 |
20160074340 | VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION - The present invention is directed to methods and dosing regimens for the treatment of depression (preferably, treatment resistant depression), for the treatment of depression in a suicidal patient, and/or for the treatment and/or prevention of suicidality (e.g. suicidal ideations) comprising genotyping a patient to determine their Val66Met rs6265 polymorphism in BDNF and administering a ketamine, preferably esketamine, preferably intranasal esketamine, according to a dosing regimen matched to the patient's genotype. | 03-17-2016 |
20160076098 | METHODS OF DIAGNOSING AND TREATING CHRONIC PAIN - The invention includes compositions and methods useful for the diagnosis, prognosis, treatment, assessment, and characterization of inflammation or pain (e.g., neuropathic pain) in a subject in need thereof, based upon the expression level of at least one miRNA that is associated with inflammation or pain. In one aspect, the invention relates to compositions and methods for the prediction of a subject's responsiveness of a treatment of inflammation or pain. | 03-17-2016 |
20160136111 | TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE - Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful. | 05-19-2016 |
20160199304 | SINGLE-LAYER ORAL DOSE OF NEURO-ATTENUATING KETAMINE | 07-14-2016 |
20170231906 | SUBLINGUAL ANTIDEPRESSANT LOZENGE | 08-17-2017 |